WVC

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024

Retrieved on: 
Monday, April 1, 2024
CIC, COVID-19, Immunoglobulin G, Research, WVC, Novavax, NVAX, Messenger, Vaccine

New data from Novavax's ongoing research on its updated XBB.1.5 COVID-19 vaccine in participants who previously received an mRNA vaccine showed robust neutralizing antibody titers for the XBB.1.5 subvariant as well as for the currently circulating JN.1 subvariant.

Key Points: 
  • New data from Novavax's ongoing research on its updated XBB.1.5 COVID-19 vaccine in participants who previously received an mRNA vaccine showed robust neutralizing antibody titers for the XBB.1.5 subvariant as well as for the currently circulating JN.1 subvariant.
  • Data also showed that the vaccine's safety and reactogenicity profile was consistent with its prototype vaccine (NVX-CoV2373).
  • Differences observed in immunoglobulin (IgG) subclass responses and Fcγ-mediated effector functions following mRNA and protein-based COVID-19 vaccinations will be shared.
  • Novavax will also discuss its influenza and CIC vaccine candidates, including a recap of data to date and the timeline for the Phase 3 trial anticipated to start during the second half of 2024.

NBA Player Landry Shamet Teams Up with Earth's Splendor to Revolutionize Affordable Wellness Supplements

Retrieved on: 
Wednesday, March 6, 2024
Landry Shamet, NBA, Mineral, Vitamin, Health, VMS, CPC, Splendor, Washington Wizards, WVC, Partnership, Dietary supplement

This collaboration promises to elevate the brand through community engagement and digital marketing - providing consumers much needed access to affordable, lab-tested, premium-quality nutritional supplements.

Key Points: 
  • This collaboration promises to elevate the brand through community engagement and digital marketing - providing consumers much needed access to affordable, lab-tested, premium-quality nutritional supplements.
  • Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9251551-earths-splendor-wellness...
    Earth's Splendor's diverse assortment of vitamins, minerals & supplements is owned by WVC Holdings (WVC).
  • Matt Wolf, CEO, expressed his enthusiasm stating, "We are thrilled to join forces with Landry Shamet to share Earth's Splendor with a new audience.
  • This collaboration between Earth's Splendor and Landry Shamet marks a significant milestone in the health and wellness industry, demonstrating the power of accessibility and quality in nutrition.

Fear Free®, LLC Unveils a Revitalized Brand at WVC 2024

Retrieved on: 
Monday, February 19, 2024
Marketing, Pig, Cattle, Animal, Growth, Work, Food, Conference, Chicken, History, LAS, Becker, Heart, WVC

LAS VEGAS, Feb. 19, 2024 /PRNewswire-PRWeb/ -- Fear Free®, the single most transformative initiative in the history of companion animal practice, today unveiled its dynamic new brand at the 96th WVC Annual Veterinary Conference. The new brand, which embodies the company's commitment to improving the emotional and physical wellbeing of all animals, will be showcased at Fear Free's booth at WVC.

Key Points: 
  • Fear Free® Unveils New Branding at 96th WVC Annual Veterinary Conference, Emphasizing Enhanced Animal Wellbeing and Expanded Services.
  • LAS VEGAS, Feb. 19, 2024 /PRNewswire-PRWeb/ -- Fear Free®, the single most transformative initiative in the history of companion animal practice, today unveiled its dynamic new brand at the 96th WVC Annual Veterinary Conference.
  • The new brand, which embodies the company's commitment to improving the emotional and physical wellbeing of all animals, will be showcased at Fear Free's booth at WVC.
  • Andru Valpy, Marketing Manager for Fear Free, expressed excitement about the new brand's debut: "Revealing our new brand is a milestone moment.

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE WESTERN VETERINARY CONFERENCE IN LAS VEGAS, NEVADA

Retrieved on: 
Tuesday, February 13, 2024
Pet, Osteoarthritis, Animal, Joint, Veterinarian, Conference, Arthralgia, WVC, Mandalay Bay Convention Center, Video game

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology, an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles.

Key Points: 
  • PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology, an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles.
  • The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
  • WVC is the largest veterinary conference that services the western part of the United States, and normally plays host to more than 15,000+ participants including many of the top industry professionals.
  • “We are incredibly excited to participate in this year’s Western Veterinary Conference.

Roo Reveals Remarkable Earnings Potential Generational Shifts toward Flexible Work among Veterinarians Nationwide

Retrieved on: 
Monday, January 8, 2024
Workforce, WVC, Roo, Economy, Millennials, SAN, VMX, Mental health, Job satisfaction, Veterinary medicine, AVMA, Veterinarian

SAN FRANCISCO, Jan. 8, 2024 /PRNewswire/ -- Roo Veterinary Inc., the leading veterinary staffing solutions marketplace, has unveiled compelling data showcasing the significant earnings veterinarians can achieve through embracing flexible work.

Key Points: 
  • SAN FRANCISCO, Jan. 8, 2024 /PRNewswire/ -- Roo Veterinary Inc., the leading veterinary staffing solutions marketplace, has unveiled compelling data showcasing the significant earnings veterinarians can achieve through embracing flexible work.
  • 64% of Roo veterinarians and 85% of Roo technicians are under 40 as Millennials now make up the largest percentage of veterinarians2.
  • As the demand for veterinary care rises, Roo is dedicated to expanding its platform to meet the needs of veterinarians and the communities they serve.
  • In 2024, Roo will be returning to major veterinary conferences VMX, WVC, and AVMA where veterinarians and technicians will be able to sign-up on site instantly at Roo's booth.

Trends in wildlife-vehicle collisions can guide prevention strategies in Canada

Retrieved on: 
Tuesday, November 28, 2023
Roadkill, TIRF, Fatality, Bison, Bird, WVC, Death, Collection, Movement, Person, Duck, Human, Education, Animal, Coyote, Autumn, Deer, Safety, Fox, Desjardins Insurance, Wolf, Hunting

OTTAWA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Traffic Injury Research Foundation (TIRF) has released a new fact sheet, Wildlife-Vehicle Collisions in Canada, 2000-2020 made possible by sponsorship from Desjardins Insurance .

Key Points: 
  • OTTAWA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Traffic Injury Research Foundation (TIRF) has released a new fact sheet, Wildlife-Vehicle Collisions in Canada, 2000-2020 made possible by sponsorship from Desjardins Insurance .
  • It examines the magnitude, characteristics and trends related to motor vehicle fatalities involving wildlife collisions in Canada from 2000 to 2020.
  • Only one in three (177) wildlife-vehicle collisions occur in the Fall despite this being a peak period for animal migration.
  • Information about the types of wildlife involved in collisions is key to guide the selection of wildlife mitigation measures.

Novavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023

Retrieved on: 
Wednesday, October 11, 2023
COVID-19, Omicron, WVC, NVAX, Vaccine, Development, Research and development, MD, Ageing, Virus, Science, CIC, Messenger, Novavax, EU, Pharmaceutical industry, Research

GAITHERSBURG, Md., Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023 , October 11-15, and three oral presentations at World Vaccine Congress (WVC) Europe 2023, October 16-19.

Key Points: 
  • GAITHERSBURG, Md., Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023 , October 11-15, and three oral presentations at World Vaccine Congress (WVC) Europe 2023, October 16-19.
  • Highlights include clinical data on Novavax's BA.1, BA.5 and bivalent variant vaccines, an evaluation of its prototype COVID-19 vaccine in children aged 6 to 11 years, real-world evidence on adverse events post-COVID vaccination and an update on its COVID-19-Influenza Combination (CIC) vaccine candidate.
  • "We are excited to share the latest clinical data and real-world evidence advancing the science behind our protein-based vaccine technology," said Filip Dubovsky, MD, President of Research and Development, Novavax.
  • "These data will support the expansion of our label and describe characteristics that may help drive vaccine choice."

Novavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023

Retrieved on: 
Wednesday, October 11, 2023
COVID-19, Omicron, WVC, NVAX, Vaccine, Development, Research and development, MD, Ageing, Virus, Science, CIC, Messenger, Novavax, EU, Pharmaceutical industry, Research

GAITHERSBURG, Md., Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023 , October 11-15, and three oral presentations at World Vaccine Congress (WVC) Europe 2023, October 16-19.

Key Points: 
  • GAITHERSBURG, Md., Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023 , October 11-15, and three oral presentations at World Vaccine Congress (WVC) Europe 2023, October 16-19.
  • Highlights include clinical data on Novavax's BA.1, BA.5 and bivalent variant vaccines, an evaluation of its prototype COVID-19 vaccine in children aged 6 to 11 years, real-world evidence on adverse events post-COVID vaccination and an update on its COVID-19-Influenza Combination (CIC) vaccine candidate.
  • "We are excited to share the latest clinical data and real-world evidence advancing the science behind our protein-based vaccine technology," said Filip Dubovsky, MD, President of Research and Development, Novavax.
  • "These data will support the expansion of our label and describe characteristics that may help drive vaccine choice."

Restaurant365 Announces First National Two-Day User Conference

Retrieved on: 
Thursday, July 20, 2023
Intelligence, Food & Wine, Controller, Food, Workforce, Restaurant, CFO, City, Growth, James Beard Foundation Award: 2010s, R, Iron Chef, Treasurer, WVC, Accounting, RTT, Video game

IRVINE, Calif., July 20, 2023 /PRNewswire/ -- Restaurant365, the leading all-in-one restaurant enterprise management software, has announced its first national two-day user conference will be held in Austin, Texas on July 30 – August 1, 2023.

Key Points: 
  • IRVINE, Calif., July 20, 2023 /PRNewswire/ -- Restaurant365 , the leading all-in-one restaurant enterprise management software, has announced its first national two-day user conference will be held in Austin, Texas on July 30 – August 1, 2023.
  • "RTT gives us the opportunity to connect and collaborate with R365 users on a new level in the convenience of their own cities," states Katie Fairchild, Chief Marketing Officer at Restaurant365.
  • "We received a lot of feedback about the positive impact of the one-day RTT events in Miami, Los Angeles, and San Francisco.
  • Award-winning chef and restaurant owner, Stephanie Izard, will headline the two-day conference with a keynoted talk.

aVaxziPen Announces Positive Data in Multiple Diseases on Novel Needle-Free Vaccine, Thermally Stable Delivery Platform at World Vaccine Congress

Retrieved on: 
Monday, April 3, 2023
Vaccine, Antigen, CSO, Needle, Vaccine hesitancy, Psychosocial treatment of needle phobia in children, Congress, Tetanus, WVC, Anthrax, Syringe

OXFORD, United Kingdom, April 03, 2023 (GLOBE NEWSWIRE) -- aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, announces the presentation of data at the World Vaccine Congress (WVC) in Washington, USA.

Key Points: 
  • OXFORD, United Kingdom, April 03, 2023 (GLOBE NEWSWIRE) -- aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, announces the presentation of data at the World Vaccine Congress (WVC) in Washington, USA.
  • The company will present a poster entitled, “Needle-free, injectable solid dose vaccine delivery generates equivalent immune response with different antigens and animal models”.
  • The immunogenicity data from four in vivo models reinforces the value of the company’s needle-free solid-dose vaccine platform as a novel way to effectively deliver vaccines for tetanus, anthrax, influenza, and peanut allergy.
  • Dr Keith Howard, aVaxziPen’s CSO, said, “With our needle-free technology we’re on a mission to transform vaccine delivery for the benefit of communities around the world.